항악성종양제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 9.1%의 CAGR로 2,021억 2,200만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 환자 교육 및 인식 개선, 정부 이니셔티브, 맞춤형 암 치료에 대한 수요 증가, 암 치료에서 삶의 질에 대한 중요성 증가에 기인하는 것으로 추정됩니다. 예측 기간 동안 주요 동향으로는 암 연구의 발전, 표적 치료제 개발, 생명공학 혁신, 진단 도구의 발전 등이 있습니다.
암 발병률의 증가는 향후 항악성종양제 시장의 확대를 촉진할 것으로 예상됩니다. 암은 신체의 거의 모든 장기나 조직에 발생할 수 있는 질병군을 말하며, 비정상적인 세포가 통제할 수 없을 정도로 증식하여 정상 경계를 넘어 다른 장기로 전이되거나 주변으로 침범하여 발생합니다. 항악성종양제는 DNA 손상, 세포주기 교란, 주요 세포 과정 억제 등 다양한 기전을 통해 암세포의 증식과 분열을 막는 작용을 하기 때문에 암 치료에 있어 매우 중요합니다. 예를 들어, 2024년 2월 프랑스에 본부를 두고 암 연구의 국제 협력을 촉진하는 세계적인 기구인 국제암연구소(IARC)는 2050년까지 전 세계 암 환자 수가 3500만 명을 넘어 2022년 추정치인 2,000만 명에서 77% 증가할 것으로 예측했습니다. 이에 따라 암 환자 수의 증가가 항악성종양제 시장 성장에 박차를 가하고 있습니다.
항악성종양제 시장의 성장은 암 연구에 대한 투자 증가에 의해 주도될 것으로 예상됩니다. 이러한 투자에는 암의 연구, 예방, 진단 및 치료를 위한 과학적 시도를 지원하기 위한 재정적 자원을 할당하는 것이 포함됩니다. 암 연구에 대한 추가 자금을 통해 제약 및 바이오테크놀러지 기업들은 잠재적인 신약 타겟을 식별하고 후보 화합물을 만드는 등 새로운 항악성 종양 치료제를 탐색, 개발 및 엄격하게 테스트할 수 있습니다. 예를 들어, 2022년 3월, 호주 보건 및 노인 의료부는 암 서비스와 결과를 개선하기 위해 8억 9,350만 달러의 예산을 배정했습니다. 이 투자의 일부인 3억 2,940만 달러는 트로델비, 림프루자, 마일로타그와 같은 새로운 암 치료제에 사용되어 연간 수백 명의 환자에게 혜택을 줄 수 있습니다. 결과적으로, 암 연구에 대한 투자 증가는 항악성종양제 시장의 성장을 촉진할 것입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 항악성종양제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
- 최종 이용 산업 분석
- 세계의 항악성종양제 시장 : 성장률 분석
- 세계의 항악성종양제 시장 실적 : 규모와 성장, 2019-2024
- 세계의 항악성종양제 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 항악성종양제 전체 시장(TAM)
제6장 시장 세분화
- 세계의 항악성종양제 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 알킬화제
- 대사길항물질
- 호르몬과 길항제
- 기타
- 세계의 항악성종양제 시장 : 질환 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 소화기암
- 전립선암
- 폐암
- 유방암
- 기타 질병 종류
- 세계의 항악성종양제 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원
- 클리닉
- 암 재활 센터
- 외래 수술 센터
- 세계의 항악성종양제 시장 알킬화제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 질소 머스터드
- 알킬 설폰산염
- 니트로소 요소
- 트리아진
- 세계의 항악성종양제 시장 대사길항제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 푸린 유사체
- 피리미딘 유사체
- 엽산 길항제
- 세계의 항악성종양제 시장, 호르몬과 길항제 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 에스트로겐과 항에스트로겐
- 안드로겐과 항안드로겐
- 글루코코르티코이드
- 세계의 항악성종양제 시장, 기타, 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 빈카 알칼로이드
- 타키산
- 항생제 항종양제
- 표적 치료제
제7장 지역별·국가별 분석
- 세계의 항악성종양제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 항악성종양제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 항악성종양제 시장 : 경쟁 구도
- 항악성종양제 시장 : 기업 개요
- Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- Novartis AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- Fresenius SE & Co. KGaA
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim International GmbH
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Eisai Co. Ltd.
- Sun Pharmaceutical Industries Limited
- Ipsen SA
- Cipla Limited
- Dr. Reddy's Laboratories Ltd.
- Intas Pharmaceuticals Limited
- Hikma Pharmaceuticals PLC
- Gland Pharma Limited
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
- 항악성종양제 시장 2029 : 새로운 기회를 제공하는 국가
- 항악성종양제 시장 2029 : 새로운 기회를 제공하는 부문
- 항악성종양제 시장 2029 : 성장 전략
제36장 부록
ksm
Anti-neoplastic agents refer to drugs that inhibit or destroy abnormal tissue growth, specifically targeting and combating cancerous cells in the body. They have a vital role in cancer treatment by disrupting the processes involved in tumor development and progression.
The main types of anti-neoplastic agents are alkylating agents, antimetabolites, hormones and antagonists and miscellaneous. Alkylating agents are a class of chemical compounds that can add alkyl groups to DNA, RNA and proteins, disrupting their normal function and interfering with cell replication. These are used to treat several diseases, including gastrointestinal cancer, prostate cancer, lung cancer, breast cancer and others and are used by various end users, such as hospitals, clinics, cancer rehabilitation centers and ambulatory surgical centers.
The anti-neoplastic agents market research report is one of a series of new reports from The Business Research Company that provides anti-neoplastic agents market statistics, including anti-neoplastic agent industry global market size, regional shares, competitors with an anti-neoplastic agent market share, detailed anti-neoplastic agents market segments, market trends and opportunities and any further data you may need to thrive in the anti-neoplastic agent industry. This anti-neoplastic agent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The anti-neoplastic agents market size has grown strongly in recent years. It will grow from $130.01 billion in 2024 to $142.82 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to increasing cancer incidence, growing demand for therapies, rising demand for minimally invasive cancer treatments, demand for affordable anti-neoplastic treatments.
The anti-neoplastic agents market size is expected to see strong growth in the next few years. It will grow to $202.12 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to patient education and awareness, government initiative, growing demand for personalized cancer treatment, growing focus on quality of life in cancer treatment. Major trends in the forecast period include advancements in oncology research, development of targeted therapies, biotechnology innovation, advancements in diagnostic tools.
The growing incidence of cancer is anticipated to drive the expansion of the antineoplastic agent market in the future. Cancer refers to a group of diseases that can arise in nearly any organ or tissue within the body, occurring when abnormal cells grow uncontrollably, surpass their usual boundaries, and either spread to other organs or invade surrounding areas. Antineoplastic agents are crucial in the treatment of cancer as they work to prevent the growth and division of cancerous cells through various mechanisms, such as causing DNA damage, disrupting the cell cycle, and interfering with key cellular processes. For example, in February 2024, the International Agency for Research on Cancer (IARC), a global organization based in France that fosters international cooperation in cancer research, projected that the global cancer burden will exceed 35 million by 2050, representing a 77% increase from the estimated 20 million in 2022. As a result, the rising number of cancer cases is fueling the growth of the antineoplastic agent market.
The growth of the anti-neoplastic agent market is expected to be driven by an increase in investment in cancer research. This investment involves allocating financial resources to support scientific endeavors aimed at studying, preventing, diagnosing, and treating cancer. The additional funding for cancer research enables pharmaceutical and biotechnology companies to explore, develop, and rigorously test new anti-neoplastic agents, which includes identifying potential drug targets and creating candidate compounds. For example, in March 2022, the Australian Department of Health and Aged Care allocated $893.5 million to improve cancer services and outcomes. A portion of this investment, $329.4 million, is earmarked for new cancer drugs like Trodelvy, Lynparza, and Mylotarg, which can potentially benefit hundreds of patients annually. Consequently, the increased investment in cancer research is poised to drive the growth of the anti-neoplastic agent market.
Leading companies in the field of anti-neoplastic agents are dedicated to the development of clinical practices to maintain their market position. For instance, in March 2022, Novartis AG, a pharmaceutical company headquartered in Switzerland, announced the approval of Pluvicto by the Food and Drug Administration (FDA). Pluvicto is the first targeted radioligand therapy approved for the treatment of progressive metastatic castration-resistant prostate cancer (mCRPC) that is positive for PSMA (Prostate-specific membrane antigen). The recommended treatment regimen involves administering 7.4 GBq (200 mCi) of Pluvicto intravenously every six weeks for a maximum of six doses, with treatment cessation upon disease progression or if intolerable toxicity occurs, whichever happens first. Patient selection for Pluvicto treatment in previously treated mCRPC should be based on the assessment of PSMA expression in tumors, employing Locametz or another authorized PSMA-11 imaging agent.
In August 2022, Ipsen SA, a biopharmaceutical company headquartered in France, completed the acquisition of Epizyme Inc. for a total of $247 million. This strategic move by Ipsen is intended to broaden its oncology portfolio by incorporating Tazverik, an innovative EZH2 inhibitor that offers a chemotherapy-free treatment option. Epizyme Inc., based in the United States, is a biopharmaceutical company known for its contributions in the field of anti-neoplastic agents.
Major companies operating in the anti-neoplastic agents market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Ipsen SA, Cipla Limited, Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Gland Pharma Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Ltd., Lantheus Holdings Inc., Hutchison Medipharma Ltd., Natco Pharma Ltd., Accord Healthcare Limited, Qilu Pharmaceutical Co. Ltd.
North America was the largest region in the anti-neoplastic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-neoplastic agents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the anti-neoplastic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The anti-neoplastic agents market consists of sales of antitumor antibiotics, microtubule inhibitors and topoisomerase inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Anti-Neoplastic Agents Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on anti-neoplastic agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for anti-neoplastic agents ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anti-neoplastic agents market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Alkylating Agents; Antimetabolites; Hormones And Antagonists; Miscellaneous
- 2) By Disease Type: Gastrointestinal Cancer; Prostate Cancer; Lung Cancer; Breast Cancer; Other Disease Types
- 3) By End User: Hospitals; Clinics; Cancer Rehabilitation Centers; Ambulatory Surgical Centers
- Subsegments:
- 1) By Alkylating Agents: Nitrogen Mustards; Alkyl Sulfonates; Nitrosoureas; Triazines
- 2) By Antimetabolites: Purine Analogues; Pyrimidine Analogues; Folate Antagonists
- 3) By Hormones and Antagonists: Estrogens and Antiestrogens; Androgens and Antiandrogens; Glucocorticoids
- 4) By Miscellaneous: Vinca Alkaloids; Taxanes; Antibiotic Antineoplastics; Targeted Therapy Agents
- Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bayer AG; Novartis AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Anti-Neoplastic Agents Market Characteristics
3. Anti-Neoplastic Agents Market Trends And Strategies
4. Anti-Neoplastic Agents Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Anti-Neoplastic Agents Growth Analysis And Strategic Analysis Framework
- 5.1. Global Anti-Neoplastic Agents PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Anti-Neoplastic Agents Market Growth Rate Analysis
- 5.4. Global Anti-Neoplastic Agents Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Anti-Neoplastic Agents Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Anti-Neoplastic Agents Total Addressable Market (TAM)
6. Anti-Neoplastic Agents Market Segmentation
- 6.1. Global Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Alkylating Agents
- Antimetabolites
- Hormones And Antagonists
- Miscellaneous
- 6.2. Global Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Gastrointestinal Cancer
- Prostate Cancer
- Lung Cancer
- Breast Cancer
- Other Disease Types
- 6.3. Global Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinics
- Cancer Rehabilitation Centers
- Ambulatory Surgical Centers
- 6.4. Global Anti-Neoplastic Agents Market, Sub-Segmentation Of Alkylating Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Nitrogen Mustards
- Alkyl Sulfonates
- Nitrosoureas
- Triazines
- 6.5. Global Anti-Neoplastic Agents Market, Sub-Segmentation Of Antimetabolites, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Purine Analogues
- Pyrimidine Analogues
- Folate Antagonists
- 6.6. Global Anti-Neoplastic Agents Market, Sub-Segmentation Of Hormones and Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Estrogens and Antiestrogens
- Androgens and Antiandrogens
- Glucocorticoids
- 6.7. Global Anti-Neoplastic Agents Market, Sub-Segmentation Of Miscellaneous, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Vinca Alkaloids
- Taxanes
- Antibiotic Antineoplastics
- Targeted Therapy Agents
7. Anti-Neoplastic Agents Market Regional And Country Analysis
- 7.1. Global Anti-Neoplastic Agents Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Anti-Neoplastic Agents Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Anti-Neoplastic Agents Market
- 8.1. Asia-Pacific Anti-Neoplastic Agents Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Anti-Neoplastic Agents Market
- 9.1. China Anti-Neoplastic Agents Market Overview
- 9.2. China Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Anti-Neoplastic Agents Market
- 10.1. India Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Anti-Neoplastic Agents Market
- 11.1. Japan Anti-Neoplastic Agents Market Overview
- 11.2. Japan Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Anti-Neoplastic Agents Market
- 12.1. Australia Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Anti-Neoplastic Agents Market
- 13.1. Indonesia Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Anti-Neoplastic Agents Market
- 14.1. South Korea Anti-Neoplastic Agents Market Overview
- 14.2. South Korea Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Anti-Neoplastic Agents Market
- 15.1. Western Europe Anti-Neoplastic Agents Market Overview
- 15.2. Western Europe Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Anti-Neoplastic Agents Market
- 16.1. UK Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Anti-Neoplastic Agents Market
- 17.1. Germany Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Anti-Neoplastic Agents Market
- 18.1. France Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Anti-Neoplastic Agents Market
- 19.1. Italy Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Anti-Neoplastic Agents Market
- 20.1. Spain Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Anti-Neoplastic Agents Market
- 21.1. Eastern Europe Anti-Neoplastic Agents Market Overview
- 21.2. Eastern Europe Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Anti-Neoplastic Agents Market
- 22.1. Russia Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Anti-Neoplastic Agents Market
- 23.1. North America Anti-Neoplastic Agents Market Overview
- 23.2. North America Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Anti-Neoplastic Agents Market
- 24.1. USA Anti-Neoplastic Agents Market Overview
- 24.2. USA Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Anti-Neoplastic Agents Market
- 25.1. Canada Anti-Neoplastic Agents Market Overview
- 25.2. Canada Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Anti-Neoplastic Agents Market
- 26.1. South America Anti-Neoplastic Agents Market Overview
- 26.2. South America Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Anti-Neoplastic Agents Market
- 27.1. Brazil Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Anti-Neoplastic Agents Market
- 28.1. Middle East Anti-Neoplastic Agents Market Overview
- 28.2. Middle East Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Anti-Neoplastic Agents Market
- 29.1. Africa Anti-Neoplastic Agents Market Overview
- 29.2. Africa Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Anti-Neoplastic Agents Market Competitive Landscape And Company Profiles
- 30.1. Anti-Neoplastic Agents Market Competitive Landscape
- 30.2. Anti-Neoplastic Agents Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
31. Anti-Neoplastic Agents Market Other Major And Innovative Companies
- 31.1. Bristol-Myers Squibb Company
- 31.2. AstraZeneca PLC
- 31.3. Fresenius SE & Co. KGaA
- 31.4. Takeda Pharmaceutical Company Limited
- 31.5. Boehringer Ingelheim International GmbH
- 31.6. Viatris Inc.
- 31.7. Teva Pharmaceutical Industries Ltd.
- 31.8. Eisai Co. Ltd.
- 31.9. Sun Pharmaceutical Industries Limited
- 31.10. Ipsen SA
- 31.11. Cipla Limited
- 31.12. Dr. Reddy's Laboratories Ltd.
- 31.13. Intas Pharmaceuticals Limited
- 31.14. Hikma Pharmaceuticals PLC
- 31.15. Gland Pharma Limited
32. Global Anti-Neoplastic Agents Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Anti-Neoplastic Agents Market
34. Recent Developments In The Anti-Neoplastic Agents Market
35. Anti-Neoplastic Agents Market High Potential Countries, Segments and Strategies
- 35.1 Anti-Neoplastic Agents Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Anti-Neoplastic Agents Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Anti-Neoplastic Agents Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
